Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Tactile Systems Technology, Inc.

Capitalization 613M 536M 484M 463M 842M 56.67B 875M 5.78B 2.29B 27.07B 2.3B 2.25B 97.78B P/E ratio 2026 *
23.7x
P/E ratio 2027 * 18.5x
Enterprise value 613M 536M 484M 463M 842M 56.67B 875M 5.78B 2.29B 27.07B 2.3B 2.25B 97.78B EV / Sales 2026 *
1.7x
EV / Sales 2027 * 1.56x
Free-Float
98.05%
Yield 2026 *
-
Yield 2027 * -
1 day-2.32%
1 week-6.53%
Current month-8.06%
1 month+1.81%
3 months-3.20%
6 months+99.33%
Current year-7.14%
1 week 26.3
Extreme 26.295
29.06
1 month 26.3
Extreme 26.295
37.77
Current year 26
Extreme 26
37.77
1 year 8.61
Extreme 8.6098
37.77
3 years 8.61
Extreme 8.6098
37.77
5 years 6.28
Extreme 6.28
61.13
10 years 6.28
Extreme 6.28
76.63
Manager TitleAgeSince
Chief Executive Officer 60 30/06/2024
Director of Finance/CFO 51 19/03/2023
Chief Operating Officer - 31/10/2021
Director TitleAgeSince
Chairman 66 31/08/2015
Director/Board Member 67 19/09/2017
Director/Board Member 60 31/12/2020
Change 5d. change 1-year change 3-years change Capi.($)
-2.32%-6.53%+104.64%+73.97% 613M
+0.36%-0.73%+23.31%+29.62% 13.19B
-0.01%+0.04%+4.33%-1.90% 9.16B
-0.68%-3.50%-15.50%-17.27% 5.46B
+0.03%-1.68%-2.47%+14.96% 5.25B
+0.10%-6.22%+30.09%+36.26% 5.14B
-0.27%+1.75%-6.56%+47.87% 4.8B
-4.66%-14.76% - - 4.43B
-0.98%+6.43%+13.26%-48.37% 1.81B
+1.47%-1.18%+30.10%+3.60% 1.42B
Average -0.70%-2.82%+20.13%+15.41% 5.13B
Weighted average by Cap. -0.42%-2.21%+10.75%+15.73%

Financials

2026 *2027 *
Net sales 361M 315M 285M 272M 495M 33.35B 515M 3.4B 1.35B 15.93B 1.35B 1.32B 57.54B 393M 344M 311M 297M 541M 36.39B 562M 3.71B 1.47B 17.39B 1.48B 1.45B 62.8B
Net income 25.99M 22.72M 20.53M 19.64M 35.72M 2.4B 37.13M 245M 97.18M 1.15B 97.54M 95.48M 4.15B 33.39M 29.19M 26.37M 25.22M 45.88M 3.09B 47.69M 315M 125M 1.48B 125M 123M 5.33B
Net Debt - -
Logo Tactile Systems Technology, Inc.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.
Employees
1,086
Date Price Change Volume
13/03/26 26.93 $ -2.32% 161,645
12/03/26 27.57 $ -1.04% 414,079
11/03/26 27.86 $ -0.89% 231,131
10/03/26 28.11 $ -2.94% 301,589
09/03/26 28.96 $ +0.52% 393,258
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
26.93USD
Average target price
38.00USD
Spread / Average Target
+41.11%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW